Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alphamab Oncology

Request full access

Innovative biopharmaceuticals targeting oncology and autoimmune diseases with advanced antibody therapies

Suzhou Shi, ChinaFounded 2009Biotech & Life Sciences

About Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company specializing in the development of innovative antibody therapies for the treatment of oncology and autoimmune diseases. The company focuses on creating multi-functional therapeutic antibodies, which are designed to improve efficacy and safety for patients. Alphamab's core products include KN026, KN035, KN046, and KN019, each targeting different cancer types and immune system disorders. The company primarily serves healthcare providers, hospitals, and research institutions in the global market. Alphamab operates on a business model that includes research and development, clinical trials, and partnerships with other pharmaceutical companies. Revenue is generated through product sales, licensing agreements, and milestone payments from collaborations.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019
Outcome tier
Colt$25–100M revenue

Alphamab Oncology in the Suzhou Shi ecosystem

Live from Dealroom

The Alphamab Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Heritage Provider Network
  • Janchor Partners
  • PAG
  • OrbiMed
  • Advantech Capital
  • China Ventures Fund
  • Hudson Bay Capital Management
  • Adrian Cheng

Series B and later2 investors entered at this stage

  • Adrian Cheng
  • Hudson Bay Capital Management
Employees 26 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown
Web traffic by country
3.8K monthly visits
across markets
🇺🇸 United States78.9%
🇭🇰 Hong Kong13.2%
🇯🇵 Japan7.9%
🏳️ Korea2.6%
🏳️ Republic of0%
Top 5 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alphamab Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alphamab Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.